PT-141
PT-141 (bremelanotide) is a synthetic cyclic melanocortin-receptor agonist studied for libido and sexual response; research protocols typically use 1 mg subcutaneously on an as-needed basis (range 0.2-2 mg), injected 30 minutes to 3 hours before activity.
It has been studied primarily for hypoactive sexual desire disorder in premenopausal women, with additional research exploring libido and sexual response in men.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist, structurally derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) analog melanotan II via a lactam bridge that stabilizes its cyclic conformation. Unlike PDE5 inhibitors that act peripherally through the nitric-oxide/cGMP vasodilatory pathway, bremelanotide acts centrally, nonselectively activating melanocortin receptors (notably MC4R, and MC3R) in hypothalamic and limbic circuits that research associates with regulation of sexual desire and arousal. Phase 3 research in premenopausal women characterized its effects on self-reported sexual desire and associated distress, and functional MRI studies have explored its central activity.
Bremelanotide is FDA-approved as Vyleesi (2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; other uses, including in men, are not FDA-approved and remain investigational or off-label research applications.
In research and the FDA-approved Vyleesi product it is given subcutaneously on an as-needed basis ahead of anticipated activity (the approved product dose is 1.75 mg, while compounded research protocols often reference smaller microgram-range doses), with sources cautioning against more than one dose per 24 hours.
Research and labeling indicate it is taken at least roughly 45 minutes before anticipated sexual activity.
It is generally studied on its own for sexual response and is sometimes informally combined with PDE5-inhibitor approaches, though such combinations are not established in controlled research.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.